Recent Updates — IMTX

Immatics N.V. announced updated clinical trial data from its Phase 1b study with IMA402, a PRAME-targeted TCR bispecific, showing a confirmed objective response rate (cORR) of 32% in heavily pretreated patients with high PRAME expression across solid tumors, including melanoma and ovarian cancer. The company also presented exploratory analyses for anzu-cel (IMA203), its PRAME-directed cell therapy, demonstrating durable clinical benefit in advanced melanoma. Immatics operates as a clinical-stage biotechnology company focused on precision targeting of the PRAME antigen using TCR-based therapies.

Immatics N.V. announced updated Phase 1 data for its investigational IMA203CD8 PRAME-directed TCR T-cell therapy across multiple advanced solid tumors. The analysis included 90 efficacy-evaluable patients, demonstrating an objective response rate (ORR) of 51% and a confirmed ORR of 41%. Disease control was observed in 82% of patients at week 6, with durable responses lasting over 2.5 years. In the gynecologic cancer subgroup treated at clinically relevant doses, the ORR reached 60%. The therapy showed a manageable safety profile with no maximum tolerated dose reached up to 12.5 billion cells. Immatics N.V. is a biotechnology company developing T-cell receptor (TCR) T-cell therapies for cancer.

Immatics N.V. completed an underwritten public offering of 15,535,100 ordinary shares and pre-funded warrants to purchase 4,315,304 additional shares on August 26, 2026. The transaction included the full exercise of the underwriters' option to purchase 2,589,814 extra shares. Net proceeds totaled approximately $161.1 million after deducting underwriting discounts and offering expenses. Immatics intends to use these funds for research and development, manufacturing, commercialization efforts, and general corporate purposes.

Immatics N.V. reported second quarter 2026 financial results, posting a net loss of €62.5 million ($71.2 million) on collaboration revenue of €9.1 million ($10.4 million). The company holds $448.2 million in cash and other financial assets as of June 30, 2026. Immatics announced protocol amendments for its Phase 3 SUPRAME trial of anzu-cel in advanced melanoma, shifting to a streamlined final analysis with top-line data expected in the first half of 2027, followed by a BLA submission in 2027. The company also appointed Jim Pepin as General Counsel and Corporate Secretary effective July 20, 2026, succeeding Edward Sturchio. Immatics N.V. operates in the biotechnology industry, developing precision cancer therapies targeting the PRAME antigen.